Literature DB >> 17504178

Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection.

Ubonvan Jongwutiwes1, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph.   

Abstract

BACKGROUND: Cryptococcosis is an opportunistic infection with morbidity and mortality in HIV-infected patients. Impact of antiretroviral therapy (ART) on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcosis has not been well established.
METHODS: A retrospective cohort study of HIV-infected patients with cryptococcosis during 1997-2005 was conducted. Relapse and survival rates with corresponding risk factors were determined.
RESULTS: There were 149 patients with a mean age of 33.5+/-7.4 years and 57% were male. Median CD4 cell count was 22 cells/mm(3). After exclusion of patients who died or were lost to follow-up during the first two weeks, 127 patients were eligible for the analysis of the effect of ART on relapse and survival rates. Of 127 patients, 52 received ART. The demographic data between the two groups were similar. Median time of ART initiation after cryptococcal diagnosis was 2.6 months. The most frequent ART used was NNRTI-based regimen (88.4%). Median CD4 change at six months of ART was 97 cells/mm(3) and 87.9% achieved undetectable HIV-RNA. The cumulative 75% survival (free) from relapse duration was 10.4 months in no-ART group and 41.9 months in ART group (P<0.01). The 75% survival from cryptococcal-related mortality in no-ART group was 6.4 months whereas >54 months for ART group (P<0.01). In Cox proportional hazards model, ART was the only factor that associated with lower relapse and mortality rate (P<0.01).
CONCLUSIONS: ART significantly reduced relapse and mortality rate from cryptococcosis in HIV-infected patients. ART is strongly recommended in this population and should not be delayed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504178     DOI: 10.2174/157016207780636551

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  16 in total

1.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

Authors:  Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware
Journal:  Lancet Infect Dis       Date:  2017-05-05       Impact factor: 25.071

2.  HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study.

Authors:  Somnuek Sungkanuparph; Rebecca Oyomopito; Sunee Sirivichayakul; Thira Sirisanthana; Patrick C K Li; Pacharee Kantipong; Christopher K C Lee; Adeeba Kamarulzaman; Liesl Messerschmidt; Matthew G Law; Praphan Phanuphak
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

3.  Cryptococcosis in China (1985-2010): review of cases from Chinese database.

Authors:  Chen Yuchong; Che Fubin; Chen Jianghan; Wei Fenglian; Xu Nan; Yang Minghui; Sun Yalin; Zheng Zhizhong
Journal:  Mycopathologia       Date:  2011-10-07       Impact factor: 2.574

4.  Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.

Authors:  Andrew Kambugu; David B Meya; Joshua Rhein; Meagan O'Brien; Edward N Janoff; Allan R Ronald; Moses R Kamya; Harriet Mayanja-Kizza; Merle A Sande; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

5.  Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia.

Authors:  Somnuek Sungkanuparph; Awachana Jiamsakul; Sasisopin Kiertiburanakul; Sunee Sirivichayakul; Jutarat Praparattanapan; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

6.  Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings.

Authors:  Caroline Kendi; Jeremy Penner; Julius Koech; Mary Nyonda; Craig R Cohen; Elizabeth A Bukusi; Evelyn Ngugi; Ana-Claire Lew Meyer
Journal:  Postgrad Med J       Date:  2012-10-30       Impact factor: 2.401

7.  Diagnosis and Management of Cryptococcal Relapse.

Authors:  Abdu K Musubire; David R Boulware; David B Meya; Joshua Rhein
Journal:  J AIDS Clin Res       Date:  2013-04-29

8.  Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.

Authors:  Somnuek Sungkanuparph; Chonlaphat Sukasem; Sasisopin Kiertiburanakul; Ekawat Pasomsub; Wasun Chantratita
Journal:  J Int AIDS Soc       Date:  2012-03-12       Impact factor: 5.396

Review 9.  New Insights into HIV/AIDS-Associated Cryptococcosis.

Authors:  Spinello Antinori
Journal:  ISRN AIDS       Date:  2013-02-25

10.  Major role for amphotericin B-flucytosine combination in severe cryptococcosis.

Authors:  Françoise Dromer; Claire Bernede-Bauduin; Didier Guillemot; Olivier Lortholary
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.